Baltimore, Md. From the Division of Plastic and Reconstructive Surgery, University of Maryland School of Medicine.
Plast Reconstr Surg. 2011 Feb;127(2):525-530. doi: 10.1097/PRS.0b013e3181fed5dc.
Occult breast carcinoma is occasionally found in reduction mammaplasty specimens. Historically, these patients were treated with mastectomy because the exact location of the tumor was unknown. Currently, breast conservation is the treatment of choice in 50 to 85 percent of breast cancers. The authors present a technique of routine specimen marking that allows localization of the tumor and preservation of the choice of lumpectomy.
This is a retrospective review of 866 patients who underwent reduction mammaplasty performed by a single surgeon between 1990 and 2009. Data were collected for patients who had occult cancer found in their specimens, including age, cancer risk factors, abnormality, nodal status, selected treatment, and survival status. Specimens were marked and oriented and then sent in separate bags to the pathologist.
There were 10 cases of occult carcinoma among the 866 women (1.15 percent) who underwent reduction mammaplasty. Six cancers were found in patients undergoing reduction for symptomatic macromastia [n = 629 (0.95 percent)]. Four new cancers were found in the group of patients with a personal history of cancer [n = 237 (1.69 percent)]. All 10 patients had normal preoperative mammograms. Location, size, and margin status were easily identified and patients were offered the choice of lumpectomy or mastectomy.
This article demonstrates that careful marking of reduction specimens in high-risk patients or in women older than 40 years allows the pathologist to orient, localize, and further section tissue for margin status. Communication among plastic surgeon, pathologist, oncologist, and radiation therapist preserves the choice of breast conserving therapy for early cancers.
在乳房缩小成形术标本中偶尔会发现隐匿性乳腺癌。历史上,由于肿瘤的确切位置未知,这些患者通常接受乳房切除术治疗。目前,在 50%至 85%的乳腺癌患者中,保乳治疗是首选。作者提出了一种常规标本标记技术,可定位肿瘤并保留保乳手术的选择。
这是一项回顾性研究,纳入了 1990 年至 2009 年间由同一位外科医生进行的 866 例乳房缩小成形术患者。收集了在标本中发现隐匿性癌症的患者的数据,包括年龄、癌症危险因素、异常情况、淋巴结状态、选择的治疗方法和生存状况。标本被标记和定向,然后分别装袋送到病理科。
在接受乳房缩小成形术的 866 名女性中(1.15%),有 10 例隐匿性癌。6 例癌症发生在因症状性巨乳症而行乳房缩小术的患者中(n=629,0.95%)。在有癌症个人史的患者组中发现了 4 例新的癌症(n=237,1.69%)。所有 10 例患者术前乳腺 X 线检查均正常。肿瘤的位置、大小和切缘状态均容易识别,患者可选择保乳手术或乳房切除术。
本文表明,在高风险患者或年龄大于 40 岁的女性中,仔细标记乳房缩小标本可使病理学家能够定向、定位并进一步对组织进行切缘状态分析。整形外科医生、病理学家、肿瘤学家和放射治疗师之间的沟通可保留早期癌症的保乳治疗选择。